Now Playing
Opinion|Videos|June 28, 2024
Recent Trends and Innovations in the Management of CLL
Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How has the story of CLL treatment evolved in recent history? What are the latest trends and innovations you have observed in the treatment and management of CLL leading up to ASCO 2024?
- Coming into ASCO 2024, what would you consider to be the largest unmet needs in the treatment and management of CLL?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.
Results from the phase 3 DeLLphi-305 trial, presented at ESMO 2026 and published in the New England Journal of Medicine, showed median overall survival of 21.1 months with the combination vs 12.7 months with durvalumab alone.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.
The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.
Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
US Measles Outbreaks Cost Nearly $83 Million in 2026
5